Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Where Does Genzyme See Alemtuzumab For MS? After Gilenya, Before Tysabri

This article was originally published in The Pink Sheet Daily

Executive Summary

Genzyme laid out its strategy for getting alemtuzumab to peak sales of $3.5 billion in an effort to convince investors - and Sanofi - that it's worth more money.
Advertisement

Related Content

Sanofi/Genzyme Primed Patient Community For Campath’s Removal From Commercial Distribution
No Homerun, But A Base Hit For Teva's Laquinimod
No Homerun, But A Base Hit For Teva's Laquinimod
Au Revoir Genzyme; Sanofi Stakes Its Claim With $20.1 Billion Upfront And CVRs
Au Revoir Genzyme; Sanofi Stakes Its Claim With $20.1 Billion Upfront And CVRs
Genzyme, Sanofi Mum On Merger Negotiations At JPM Conference
Genzyme, Sanofi Mum On Merger Negotiations At JPM Conference
Sanofi Extends $69-Per-Share Tender Offer For Genzyme To Jan. 21
Sanofi Extends $69-Per-Share Tender Offer For Genzyme To Jan. 21

Topics

Advertisement
UsernamePublicRestriction

Register

PS071645

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel